Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 14/20 | 0.72 |
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.72 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 3/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8154134 | 0.85 | PARP11 (0.68) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL8155722 | 0.84 | PARP11 (1.00) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL8156296 | 0.82 | PARP10 (1.00) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL8167365 | 0.79 | PARP11 (0.68) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL8155829 | 0.79 | PARP11 (0.68) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL16561672 | 0.77 | PARP10 (0.76) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL8159245 | 0.76 | PARP10 (1.00) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL8154135 | 0.76 | PARP10 (0.69) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL25292799 | 0.76 | PARP11 (0.82) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL20294456 | 0.75 | CD274 (0.80) | CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| WO-2018119263-A1 | HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119263-A1 | HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | PARP11 1317/4885PARP10 2448/4885PDPK1 27/4885 |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | PARP11 1317/4885PARP10 2448/4885PDPK1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.